六味地黄丸经PI3K/Akt通路改善多囊卵巢综合征胰岛素敏感性
该研究以来曲唑联合高脂饮食诱导PCOS-IR大鼠模型,观察六味地黄丸对PI3K/Akt通路及卵巢功能的影响。结果显示六味地黄丸(3.6 g kg-1·day-1)可逆转IRS-1、PI3Kp85α、Akt、FoxO1a磷酸化异常,改善胰岛素抵抗并调节性激素水平,减轻卵巢多囊样改变。
要点
- 六味地黄丸可改善PCOS-IR大鼠的胰岛素抵抗指标
- 六味地黄丸调节FSH、雌二醇、孕酮升高及LH、睾酮降低
- 六味地黄丸减轻卵巢多囊样改变并减少闭锁卵泡
核心结论
- 六味地黄丸通过上调Cyp19a1改善卵巢多囊病理并恢复卵泡发育。
- 六味地黄丸通过作用于PI3K/Akt信号通路减轻胰岛素抵抗。
研究设计与样本
- 采用来曲唑(1 mg kg-1·day-1灌胃)联合高脂饮食21天诱导雌性Sprague-Dawley大鼠PCOS-IR模型。
- 同期灌胃二甲双胍(200 mg kg-1·day-1)或六味地黄丸(1.2或3.6 g kg-1·day-1)干预。
- 通过HE染色评估卵巢病理,放射免疫法测定血清性激素和空腹胰岛素,Western blotting检测IRS-1、PI3Kp85α、Akt、FoxO1a蛋白表达,qPCR检测FSHR和Cyp19a1 mRNA水平。
主要发现
- 六味地黄丸(3.6 g kg-1·day-1)显著逆转PCOS-IR大鼠IRS-1(S307)磷酸化上调和PI3Kp85α、Akt、FoxO1a磷酸化下调。
- 六味地黄丸使卵巢FSHR和Cyp19a1 mRNA水平上调。
- 六味地黄丸使胰岛素抵抗指数逐渐调整至正常。
- 六味地黄丸显著升高血清FSH、雌二醇、孕酮水平,降低LH、睾酮水平。
- 六味地黄丸减轻卵巢多囊样改变并减少闭锁卵泡。
临床怎么用
- 六味地黄丸可用于PCOS-IR患者改善胰岛素抵抗和卵巢多囊样改变,但需结合辨证(肾阴虚)使用。
- 临床可关注六味地黄丸对性激素(FSH、LH、雌二醇、睾酮、孕酮)和胰岛素抵抗指标的调节作用。
局限性
- 本研究为动物实验,结论需进一步临床研究验证。
- 六味地黄丸仅在高剂量(3.6 g kg-1·day-1)下显示显著逆转PI3K/Akt通路异常的作用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
ETHNOPHARMACOLOGICAL RELEVANCE: Polycystic ovary syndrome (PCOS) is a complex gynecological endocrine disease commonly occurred in women of childbearing age. The main hallmark of PCOS includes elevated androgen production and insulin resistance (IR). Liuwei Dihuang Pills (LWDH Pills), a commonly prescribed traditional Chinese medicine (TCM) is widely used as a tonic prescription to treat diabetes, female menopause syndrome and other symptoms with'Kidney-Yin' deficiency. It has been reported the effects LWDH pills on PI3K/Akt signaling pathway in T2DM treatment. Recent studies have also indicated that the treatment of menopausal syndrome may be associated with the ovarian sexual hormone levels regulated by LWDH pills to alleviate female infertility. However, its potential benefits on PCOS have not been fully elucidated. AIM OF THE STUDY: The primary aim of this study was to investigate the alterations of PI3K/Akt pathway in polycystic ovary syndrome-insulin resistance (PCOS-IR) progression induced by letrozole combined with high fat diet (HFD) and then to explore the detailed mechanism of LWDH Pills to alleviate PCOS. MATERIALS AND METHODS: The female Sprague-Dawley rats were continuously treated with letrozole (p.o administration at 1 mg kg-1·day-1) and HFD for 21 days to establish the PCOS-IR model. Concurrently, metformin (200 mg kg-1·day-1) or LWDH Pills was orally administrated (1.2 or 3.6 g kg-1·day-1) to intervene disease progression. The ovarian pathology was evaluated by HE (hematoxylin-eosin) staining. The serum sexual hormones, follicle stimulating hormone (FSH), luteinizing hormone (LH), estradiol, testosterone, progesterone and fasting insulin (FINS) were determined by radioimmunoassay. The protein expressions of IRS-1, PI3Kp85α, Akt and FoxO1a were analyzed by western blotting, while the mRNA levels of follicle-stimulating hormone receptor (FSHR) and Cyp19a1 in ovarian tissue were measured by qPCR. RESULTS: The upregulated phosphorylation of IRS-1 (S307), down-regulated phosphorylation of PI3Kp85α, Akt, and FoxO1a were significantly reversed by LWDH Pills (3.6 g kg-1·day-1) in PCOS-IR rats with up-regulated mRNA levels of FSHR and Cyp19a1 in ovary. Also, the index of insulin resistance was gradually adjusted to normal by LWDH Pills. The serum levels of FSH, estradiol, progesterone levels were significantly raised while LH, testosterone were reduced. The ovarian polycystic changes were alleviated while the atresia follicles were reduced. CONCLUSION: LWDH Pills therapy obviously improved the ovarian polycystic pathogenesis and regained the development of follicles via upregulating Cyp19a1, alleviated insulin resistance through acting on PI3K/Akt signaling pathway. These findings have provided scientific evidence for LWDH Pills to treat PCOS.
引用
- Qiu Z, Dong J, Xue C, et al. Liuwei Dihuang Pills alleviate the polycystic ovary syndrome with improved insulin sensitivity through PI3K/Akt signaling pathway. J Ethnopharmacol. 2019. PMID: 31185267. doi:10.1016/j.jep.2019.111965
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。